



**FOR IMMEDIATE RELEASE**

**BirchBioMed welcomes renowned dermatologist to its board of directors**

*Well-published expert backs revolutionary research*

British Columbia: BirchBioMed, a trial-stage biomedical company focused on the clinical evaluation, development and commercialization of anti-scarring drugs, autoimmune therapeutics and novel strategies for transplantation, is pleased to announce that renowned dermatologist and published expert, Dr. Charles Ellis, has joined its board of directors. Dr. Ellis has more than 30 years of experience in his field and continues to contribute in his roles at the University of Michigan Medical School, and chief of dermatology services with Veterans Affairs Ann Arbor Healthcare System.



Dr. Ellis was chosen as an Inaugural Member of the University of Michigan Medical School's League of Educational Excellence and listed among the University's Academy of Medical Educators. He has also been honored with an Award of Appreciation from the University's medical students.

Dr. Ellis is a prolific author and has published more than 280 journal articles and book chapters. He is among the dozen most-referenced dermatologists in the world, reflecting the importance of his published papers in both dermatology and high-impact general medical journals. He is the third-most cited first-author, with two of his papers having been cited over 200 times each.

He is also a multi-patent-holder and has held a number of visiting professorships; served on the editorial boards of various journals, and is a member of numerous professional organizations.

"We are thrilled to have Dr. Ellis join us in our innovative and cutting-edge research," said BirchBioMed co-founder Mark Miller. "His expertise in dermatology makes this a perfect partnership. His expertise will help us get our revolutionary treatment into the hands of physicians and patients."

BirchBioMed is a clinical-stage biomedical company focused on the clinical evaluation, development and commercialization of anti-scarring drugs, autoimmune therapeutics and novel strategies for transplantation

BirchBioMed is a University of British Columbia (UBC) spinoff, and holds the exclusive worldwide pharmaceutical license for two medical therapeutic technologies from UBC that mark significant medical breakthroughs in the treatment of fibrosis and certain autoimmune diseases.

Their patented groundbreaking anti-scar technology (FS2) is the key to unlocking several diseases and addressing untold other health concerns.

It's the only antifibrotic (or anti-scarring) therapy that prevents formation of scars and promotes the breakdown of existing scars. This small molecule drug attacks scarring at the molecular level without hindering wound healing. It radically improves healing outcomes for burn survivors and dramatically reduces post-surgical treatment costs associated with scarring.

The group has found several ways to deliver the product – topically, orally and via injection, as well as through sutures, dressings and even bandages.

The first phase of clinical trials demonstrated the safe, topical administration. It's currently in second stage trials in the U.S.

**For further information, contact:**

Susan Elliott

Chief Marketing Officer

BirchBioMed Inc.

Phone: (905) 833-0826

[susan.elliott@birchbiomed.com](mailto:susan.elliott@birchbiomed.com)

[birchbiomed.com](http://birchbiomed.com)

